Tobacco smoking modifies association between GLn-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 9, 2000, Pages 2120-2126

  Sen Banerjee, Sucharita ^a   Siles, Xinia ^b   Campos, Hannia ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Antioxidants; Coronary heart disease; Genetic epidemiology; Lipoproteins; Paraoxonase

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; GLYCINE;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; COSTA RICA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TOBACCO;

EID: 0033818770     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.9.2120     Document Type: Article

References (48)

1. Beyond cholesterol: Modifications of low-density lipoproteins that increase its atherogenicity
2. Lipoprotein oxidation in dyslipidemia: Insights into general mechanisms affecting lipoprotein oxidative behavior
3. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
4. HDL, its enzymes and its potential to influence lipid peroxidation
5. Antioxidative activity of high-density lipoproteins in vivo
6. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
7. Is paraoxonase related to atherosclerosis?
8. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein
9. The molecular basis of the human paraoxonase activity polymorphism
10. Studies on human serum paraoxonase/arylesterase
11. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
12. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations
13. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon
14. Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification
15. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
16. A variant human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
17. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
18. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
19. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
20. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
21. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese
22. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
23. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
24. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
25. The Gln-Arg, polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan
26. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
27. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase
28. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
29. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation
30. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
31. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
32. Paraoxonase. Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
33. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects
34. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
35. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
36. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus
37. Myocardiai infarction and coronary deaths in the World Health Organization MONICA project: Registration procedures, event rates, and case-fatality rates in 38 population from 21 countries in four continents
38. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
39. Compendium of physical activities: Classification of energy costs of human physical activities
40. Prevalence of cardiovascular risk factors in rural and urban Puriscal, Costa Rica
41. Paraoxonase genotypes, lipoprotein lipase activity, and HDL
42. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate
43. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism
44. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols